RMS Pty Revenue and Competitors

AU

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • RMS Pty's estimated annual revenue is currently $2.8M per year.(i)
  • RMS Pty's estimated revenue per employee is $101,500

Employee Data

  • RMS Pty has 28 Employees.(i)
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.7M814%N/AN/A
#2
$7.7M59N/AN/AN/A
#3
$4.3M37N/AN/AN/A
#4
$2.6M27N/AN/AN/A
#5
$3.8M33N/AN/AN/A
#6
$2.8M28N/AN/AN/A
#7
N/A6N/AN/AN/A
#8
$4.1M35N/AN/AN/A
#9
$3.5M30N/AN/AN/A
#10
$6.9M53-9%N/AN/A
#11
$1M12N/AN/AN/A
#12
$147M463N/AN/AN/A
#13
$74.6M267N/AN/AN/A
#14
$2M20N/AN/AN/A
#15
$68.2M244N/AN/AN/A
#16
$3M30N/AN/AN/A
#17
$1.8M12N/AN/AN/A
#18
$2.6M44N/AN/AN/A
#19
$0.6M8N/AN/AN/A
#20
$1.3M15N/AN/AN/A
Add Company

keywords:N/A

N/A

Total Funding

28

Number of Employees

$2.8M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

RMS Pty News

2022-04-17 - ABBV SHAREHOLDER ALERT: Jakubowitz Law Reminds AbbVie Shareholders of a Lead Plaintiff Deadline of June 6, 2022

sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced today. ZINBRYTA is a once-monthly, self-administered,

2022-04-17 - GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV

sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced today. ZINBRYTA is a once-monthly, self-administered,

2022-04-17 - The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CELH, VLTA and ABBV

sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced today. ZINBRYTA is a once-monthly, self-administered,

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M2833%$7M
#2
$4.1M28-3%N/A
#3
$2.8M28N/AN/A
#4
$5.3M28N/AN/A
#5
$2.8M28N/AN/A